Back

Pharmacogenetic Characterization of Cytochrome P450 Genes involved in Psychotropic Medication Metabolism in a Cohort of Patients with Prader-Willi Syndrome

Moreno-Armengol, A.; Pareja, R.; Hernandez-Lazaro, A.; Capel, L.; Corripio, R.; Caixas, A.; Baena, N.

2026-05-18 pharmacology and therapeutics
10.64898/2026.05.09.26352521 medRxiv
Show abstract

Prader-Willi syndrome (PWS) is a rare multisystemic disorder characterized by obesity, endocrine dysfunctions, and psychiatric comorbidities, which imply frequent use of psychotropic medications. They account for atypical responses to standard dosages of psychiatric drugs. Pharmacogenetics could be part of the reason for this situation, potentially offering a valuable tool for individualized treatment. This study analyzed allelic and phenotypic frequency distributions of five of the main cytochrome P450 enzymes (CYP2D6, CYP2B6, CYP2C19, CYP2C9, CYP3A4) involved in psychiatric drug metabolism in 47 patients with genetically confirmed diagnosis of PWS and compared them to reference frequencies in the general European population. Allelic frequency comparisons between the European reference population and the overall PWS cohort revealed a significant global difference for CYP2B6, with CYP2C19 and CYP2D6 showing trends toward significance. Although no global allelic differences remained significant after false discovery rate correction, post-hoc analyses consistently identified an enrichment of reduced- or non-functional alleles CYP2B619 and CYP2D610 in patients with PWS. Predicted metabolizer phenotype analyses showed a significant shift toward intermediate metabolizers of CYP3A4 in the PWS cohort, with corresponding depletion of normal metabolizers. Subgroup analyses indicated that allelic differences were more pronounced in maternal uniparental disomy and non-deletion subtypes, particularly for CYP2B6, although no significant differences were observed between PWS genetic subtypes. Overall, results imply potential differences in metabolizing activity in PWS patients, and subsequent implications in drug efficacy and tolerability. These results support the idea that pharmacogenetic testing may improve therapeutic decision-making in PWS for psychiatric treatment. Larger studies are needed to confirm these preliminary results.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Genes
144 papers in training set
Top 0.1%
12.9%
2
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.1%
12.1%
3
Frontiers in Pharmacology
111 papers in training set
Top 0.2%
8.0%
4
Scientific Reports
3612 papers in training set
Top 22%
4.4%
5
NeuroImage: Clinical
144 papers in training set
Top 0.7%
4.1%
6
PLOS ONE
5266 papers in training set
Top 34%
4.1%
7
European Neuropsychopharmacology
20 papers in training set
Top 0.1%
3.5%
8
British Journal of Clinical Pharmacology
21 papers in training set
Top 0.1%
3.5%
50% of probability mass above
9
Schizophrenia
21 papers in training set
Top 0.2%
2.5%
10
Psychiatry Research: Neuroimaging
18 papers in training set
Top 0.1%
2.4%
11
The Pharmacogenomics Journal
11 papers in training set
Top 0.1%
2.2%
12
Journal of Clinical Medicine
97 papers in training set
Top 2%
1.9%
13
Frontiers in Psychiatry
87 papers in training set
Top 1%
1.8%
14
European Child & Adolescent Psychiatry
15 papers in training set
Top 0.2%
1.8%
15
Journal of Alzheimer’s Disease
50 papers in training set
Top 0.7%
1.8%
16
Epilepsia
56 papers in training set
Top 0.4%
1.7%
17
International Journal of Molecular Sciences
494 papers in training set
Top 8%
1.7%
18
Psychological Medicine
88 papers in training set
Top 1%
1.7%
19
Translational Psychiatry
260 papers in training set
Top 3%
1.7%
20
International Journal of Neuropsychopharmacology
14 papers in training set
Top 0.2%
1.4%
21
npj Genomic Medicine
36 papers in training set
Top 0.5%
1.1%
22
Psychopharmacology
69 papers in training set
Top 0.6%
1.1%
23
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
26 papers in training set
Top 0.4%
1.0%
24
Journal of Psychopharmacology
17 papers in training set
Top 0.4%
0.9%
25
Autism Research
39 papers in training set
Top 0.4%
0.9%
26
BioData Mining
22 papers in training set
Top 0.7%
0.9%
27
American Journal of Medical Genetics Part A
17 papers in training set
Top 0.3%
0.9%
28
The FASEB Journal
194 papers in training set
Top 5%
0.9%
29
NeuroImage
903 papers in training set
Top 6%
0.6%
30
Aging
75 papers in training set
Top 2%
0.6%